SCHEMBL3256010

SCHEMBL3256010

CC(O)c1cccc(OC2CCN(C(=O)O)CC2)n1

nearest known ligand 0.39

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.39
BTK Q06187 1/20 0.39
HRH3 Q9Y5N1 1/20 0.38
NAMPT P43490 3/20 0.38
KDM5A P29375 1/20 0.38
LIPE Q05469 1/20 0.37
MGLL Q99685 1/20 0.36
GPR119 Q8TDV5 6/20 0.36
SRD5A1 P18405 1/20 0.36
PRMT5 O14744 1/20 0.36
KCNH2 Q12809 1/20 0.35
IKBKB O14920 1/20 0.35
CHUK O15111 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3612507 0.85 GPR119 (0.52) GPR119
SCHEMBL5266382 0.83 HRH3 (0.46) EPHX2BTKHRH3NAMPTGPR119
SCHEMBL3248797 0.82 GPR119 (0.36) EPHX2BTKHRH3NAMPTKDM5A
SCHEMBL5270350 0.82 HCRTR1 (0.44) EPHX2BTKGPR119KCNH2
SCHEMBL3610624 0.81 GPR119 (0.47) HRH3GPR119
SCHEMBL5267084 0.79 EPHX2 (0.41) EPHX2BTKKCNH2
SCHEMBL3251761 0.79 PRMT5 (0.42) EPHX2HRH3GPR119PRMT5IKBKB
SCHEMBL3602573 0.77 HRH3 (0.43) EPHX2BTKHRH3NAMPTGPR119
SCHEMBL3602567 0.76 MGLL (0.55) EPHX2BTKHRH3MGLLGPR119
SCHEMBL3610594 0.76 LOXL2 (0.44) EPHX2BTKSRD5A1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032563-B1 BENZIMIDAZOL SUBSTITUTED THIOPHENE DERIVATIVES WITH ACTIVITY ON PLK GLAXOSMITHKLINE LLC (US) 2010-06-02 EP disclosed
US-7615643-B2 3-[((1R)-1-{2-Chloro-3-[(1-methyl-4-piperidinyl)oxy]phenyl}ethyl)oxy]-5-[5-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-1-yl]-2-thiophenecarboxamide; polo like kinase enzyme inhibitors; anticarcinogenic agents for treating cancer SMITHKLINE BEECHAM CORPORATION (US) 2009-11-10 US disclosed
US-20090124615-A9 Benzimidazole Thiophene Compounds KUNTZ KEVIN 2009-05-14 US disclosed
US-20080300247-A1 Benzimidazole Thiophene Compounds KUNTZ KEVIN 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124615-A9 Benzimidazole Thiophene Compounds ABCB1, CYP3A5, ABCG2 EPHX2 3312/4885BTK 53/4885HRH3 1975/4885
US-20080300247-A1 Benzimidazole Thiophene Compounds ABCB1, CYP3A5, ABCG2 EPHX2 3312/4885BTK 53/4885HRH3 1975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.